Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 12/20 | 0.43 |
| ▸ | MMP3 | P08254 | 11/20 | 0.43 |
| ▸ | MMP2 | P08253 | 9/20 | 0.43 |
| ▸ | MMP9 | P14780 | 8/20 | 0.43 |
| ▸ | MMP8 | P22894 | 4/20 | 0.43 |
| ▸ | MMP13 | P45452 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.42 |
| ▸ | MMP7 | P09237 | 3/20 | 0.42 |
| ▸ | MMP14 | P50281 | 2/20 | 0.42 |
| ▸ | TNF | P01375 | 2/20 | 0.42 |
| ▸ | MMP20 | O60882 | 1/20 | 0.42 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.42 |
| ▸ | MMP10 | P09238 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1176010 | 1.00 | CA1 (0.47) | CA1CA2CA7CTSSCTSK | |
| SCHEMBL1176007 | 1.00 | CA1 (0.47) | CA1CA2CA7CTSSCTSK | |
| SCHEMBL15776181 | 0.87 | CA1 (0.42) | CA1CA2CA7CTSSCTSK | |
| SCHEMBL1174310 | 0.85 | CA1 (0.41) | CA1CA2CA7CTSSCTSK | |
| SCHEMBL7897117 | 0.85 | CA1 (0.41) | CA1CA2CA7CTSSCTSK | |
| SCHEMBL8422673 | 0.85 | CA1 (0.41) | CA1CA2CA7CTSSCTSK | |
| SCHEMBL13051146 | 0.84 | ADAM17 (0.48) | MMP1MMP3MMP2MMP9MMP8 | |
| SCHEMBL21834858 | 0.84 | CA1 (0.50) | CA1CA2CA7CTSSCTSK | |
| SCHEMBL8410837 | 0.83 | CA1 (0.46) | CA1CA2CA7CTSSCTSK | |
| SCHEMBL1213869 | 0.83 | CA2 (0.46) | CA1CA2CA7CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024249291-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | CASMA THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-8247451-B2 | ADAM10 and its uses related to infection | VANDERBILT UNIVERSITY (US) | 2012-08-21 | — | — | US | disclosed |
| US-7718691-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2010-05-18 | — | — | US | disclosed |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | VANDERBILT UNIVERSITY | 2009-09-03 | — | — | US | disclosed |
| EP-1984500-A2 | ADAM10 AND ITS USES RELATED TO INFECTION | VANDERBILT UNIVERSITY (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007084488-A2 | ADAM10 AND ITS USES RELATED TO INFECTION | VANDERBILT UNIVERSITY (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070049536-A1 | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070032434-A1 | used for the treatment or prevention of HCV or amelioration the symptoms of hepatitis C infection, by modulating the interaction of an HCV polypeptide with HCV proteases | SCHERING CORPORATION | 2007-02-08 | — | — | US | disclosed |
| WO-2005087721-A2 | COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
| EP-1101492-A1 | NOVEL REMEDIES FOR ALLERGIC DISEASES | FUJI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 2001-05-23 | — | — | EP | disclosed |
| US-6172064-B1 | METALLOPROTEASE INHIBITOR; ANTIARTHRITIC AGENTS, ANTIDIABETIC AGENTS; ANTITUMOR AGENTS | GLAXO WELLCOME INC. | 2001-01-09 | — | — | US | disclosed |
| EP-1038864-A1 | NOVEL METALLOPROTEINASE INHIBITORS | FUJI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 2000-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049536-A1 | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | SERPINB1, HAVCR2, HPN | CA1 3693/4885CA2 4115/4885CA7 3889/4885 |
| US-20070032434-A1 | used for the treatment or prevention of HCV or amelioration the symptoms of hepatitis C infection, by modulating the interaction of an HCV polypeptide with HCV proteases | HAVCR2, ENPEP, SERPINB1 | CA1 3061/4885CA2 3475/4885CA7 3553/4885 |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | ADAM10, ADAM12, ADAM17 | CA1 683/4885CA2 2383/4885CA7 1515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.